Albany Molecular Research Inc (AMRI.O) Key Developments | Reuters.com
Edition:
United States

Albany Molecular Research Inc (AMRI.O)

AMRI.O on Nasdaq

13.51USD
1 Jul 2016
Change (% chg)

$0.07 (+0.52%)
Prev Close
$13.44
Open
$13.49
Day's High
$13.73
Day's Low
$13.21
Volume
238,506
Avg. Vol
303,254
52-wk High
$22.48
52-wk Low
$12.45

Latest Key Developments (Source: Significant Developments)

Albany Molecular Research clarifies 2016 revenue guidance
Tuesday, 10 May 2016 11:34am EDT 

: AMRI clarifies 2016 revenue guidance . Company expects approximately 50% of its 2016 revenue to be realized in first half of year .Continues to expect about 40% of 2016 adjusted eps to be realized in H1,corresponding 60% in second half of year, respectively.  Full Article

AMRI posts Q1 loss of $0.29/share
Tuesday, 10 May 2016 08:00am EDT 

Albany Molecular Research Inc : AMRI announces first quarter 2016 results . Q1 GAAP loss per share $0.29 . Q1 adjusted non-GAAP earnings per share $0.07 . Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S . Q1 revenue rose 29 percent to $105.6 million . Sees FY 2016 revenue up 19 percent . Sees FY 2016 revenue $465 million to $490 million . FY adjusted diluted EPS is expected to be between $1.00 and $1.10 . Fy2016 earnings per share view $1.05, revenue view $479.2 million -- Thomson Reuters I/B/E/S . Confirms standalone full year 2016 financial guidance . Q1 contract revenue of $102.8 million, up 37% from 2015 .Sees 2016 capital expenditures of approximately $45 million.  Full Article

Albany Molecular Research Inc gives FY 2016 guidance
Wednesday, 17 Feb 2016 07:31am EST 

Albany Molecular Research Inc:Expects FY 2016 revenue to be between $465 to $490 million.Expects FY 2016 adjusted EPS to be between $1.00 and $1.10 per diluted share.  Full Article

Albany Molecular and NYCNMR form collaborative agreement
Thursday, 14 Jan 2016 08:00am EST 

Albany Molecular:Signed a collaboration agreement with the New York Center for Nanomedicine Research.Collaboration agreement to co-market their nanotechnology services to global pharmaceutical and biotechnology clients.  Full Article

Eagle Pharmaceuticals Inc and AMRI agree to jointly develop parenteral drug products
Monday, 11 Jan 2016 06:50am EST 

Eagle Pharmaceuticals Inc and Albany Molecular Research, Inc:Eagle Pharmaceuticals and AMI announce agreement to jointly develop, manufacture and commercialize parenteral drug products.Says Eagle will be responsible for U.S. commercial distribution of all approved products, once approved by the FDA.AMI will supply products to Eagle pursuant to commercial supply agreement,receive payments based on eagle's sales of products.AMI will develop, initially provide CGMP manufacturing, analytical support for registration of new product candidates.  Full Article

Albany Molecular Research Inc acquires Whitehouse Laboratories
Tuesday, 15 Dec 2015 08:14am EST 

Albany Molecular Research Inc:Acquired all the outstanding equity interests of Whitehouse Laboratories.Total consideration is $54 million in cash, and an additional $2 million in shares of AMRI common stock contingent upon Whitehouse Labs achieving certain 2015 targets.AMRI financed the transaction with cash on hand and borrowings under its $30 million revolving credit facility.Transaction is expected to be accretive in 2016 to AMRI's non-GAAP diluted earnings per share.AMRI intends to provide its 2016 financial guidance in mid-February 2016.  Full Article

Albany Molecular Research Inc and Multispan Ink collaboration agreement
Thursday, 10 Dec 2015 08:00am EST 

Albany Molecular Research Inc:Says has signed collaboration agreement with biotechnology company Multispan Inc. to co-market their G protein-coupled receptor (GPCR) drug discovery services to global pharmaceutical and biotechnology clients.Says as part of three-year agreement, AMRI gains access to Multispan's uniquely differentiated GPCR cell lines, assay capabilities and expertise.  Full Article

Albany Molecular Research Inc reaffirms FY 2015 guidance
Thursday, 5 Nov 2015 07:00am EST 

Albany Molecular Research Inc:Reiterates FY 2015 total revenue of $400 to $416 million; adjusted EPS guidance maintained at between $0.90 and $0.95 per diluted share.Expects FY 2015 Adjusted EBITDA between $75 and $78 million.FY 2015 revenue of $408 mln EBITDA of $73.48 mln and EPS of $0.92 - Thomson Reuters I/B/E/S.  Full Article

Albany Molecular Research Inc raises FY 2015 outlook
Tuesday, 15 Sep 2015 07:00am EDT 

Albany Molecular Research Inc:FY 2015 contract revenue is expected to be between $386 and $400 million, an increase of 56% at the midpoint.Expects FY 2015 Adjusted EBITDA between $75 and $78 million, up 53% at the midpoint.Expects FY 2015 Adjusted diluted EPS is expected to be between $0.90 and $0.95, compared to $0.65 in 2014.FY 2015 revenue of $380 mln EBITDA of $68 mln and EPS of $0.88 - Thomson Reuters I/B/E/S.  Full Article

Albany Molecular Research Inc announces agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients
Monday, 31 Aug 2015 07:00am EDT 

Albany Molecular Research Inc:Announces a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients.Says the collaboration combines Saneca's strength in extracting opiates from plant biomass and their expertise in developing and manufacturing controlled substance APIs with AMRI's U.S. assets and their ability to tech transfer processes into these facilities.Says the collaboration will also capitalize on AMRI's sales and marketing strength in the U.S. market.  Full Article

BRIEF-AMRI posts Q1 loss of $0.29/share

* Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S